Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 349

1.

Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer.

Joice GA, Bivalacqua TJ, Kates M.

Nat Rev Urol. 2019 Aug 21. doi: 10.1038/s41585-019-0220-4. [Epub ahead of print] Review.

PMID:
31434998
2.

Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.

Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ.

Eur Urol Oncol. 2019 Feb 26. pii: S2588-9311(19)30025-2. doi: 10.1016/j.euo.2019.01.017. [Epub ahead of print]

PMID:
31411999
3.

Spotlight on Sexual Medicine: Advances and Issues of Debate.

Bivalacqua TJ.

Eur Urol Focus. 2019 Aug 9. pii: S2405-4569(19)30207-X. doi: 10.1016/j.euf.2019.07.006. [Epub ahead of print] No abstract available.

PMID:
31405620
4.

Predictive biomarkers for drug response in bladder cancer.

Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ.

Int J Urol. 2019 Aug 1. doi: 10.1111/iju.14082. [Epub ahead of print] Review.

PMID:
31370109
5.

Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer.

Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ, Sankin A, Kates M.

Urol Oncol. 2019 Jun 26. pii: S1078-1439(19)30218-2. doi: 10.1016/j.urolonc.2019.05.018. [Epub ahead of print]

PMID:
31255541
6.

Regenerative and engineered options for urethroplasty.

Pederzoli F, Joice G, Salonia A, Bivalacqua TJ, Sopko NA.

Nat Rev Urol. 2019 Aug;16(8):453-464. doi: 10.1038/s41585-019-0198-y. Epub 2019 Jun 6. Review.

PMID:
31171866
7.

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA.

Eur Urol. 2019 Aug;76(2):200-206. doi: 10.1016/j.eururo.2019.04.036. Epub 2019 May 12.

PMID:
31092337
8.

Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.

Pederzoli F, Murati Amador B, Samarska I, Lombardo KA, Kates M, Bivalacqua TJ, Matoso A.

Hum Pathol. 2019 Aug;90:1-7. doi: 10.1016/j.humpath.2019.04.018. Epub 2019 May 6.

PMID:
31071342
9.

Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor.

Hassan O, Murati Amador B, Lombardo KA, Salles D, Cuello F, Marwaha AS, Daniels MJ, Kates M, Bivalacqua TJ, Matoso A.

World J Urol. 2019 Apr 27. doi: 10.1007/s00345-019-02782-y. [Epub ahead of print]

PMID:
31030230
10.

Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.

Eich ML, Rodriguez Pena MDC, Springer SU, Taheri D, Tregnago AC, Salles DC, Bezerra SM, Cunha IW, Fujita K, Ertoy D, Bivalacqua TJ, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Netto GJ.

Mod Pathol. 2019 Apr 25. doi: 10.1038/s41379-019-0276-y. [Epub ahead of print]

PMID:
31028363
11.

Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.

Eich ML, Chaux A, Guner G, Taheri D, Mendoza Rodriguez MA, Rodriguez Peña MDC, Baras AS, Hahn NM, Drake C, Sharma R, Bivalacqua TJ, Rezaei K, Netto GJ.

Hum Pathol. 2019 Jul;89:24-32. doi: 10.1016/j.humpath.2019.04.003. Epub 2019 Apr 24.

PMID:
31026471
12.

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.

Nat Rev Urol. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4. Review.

PMID:
31019310
13.

Intratunical injection of autologous adipose stromal vascular fraction reduces collagen III expression in a rat model of chronic penile fibrosis.

Hakim L, Fiorenzo S, Hedlund P, Montorsi F, Bivalacqua TJ, De Ridder D, Weyne E, Ralph D, Garaffa G, Muneer A, Joniau S, Albersen M, Castiglione F; Trauma and Reconstructive Urology Working Party of the European Association of Urology (EAU) Young Academic Urologists (YAU).

Int J Impot Res. 2019 Apr 15. doi: 10.1038/s41443-019-0136-9. [Epub ahead of print]

PMID:
30988428
14.

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC.

Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5.

PMID:
30952638
15.

In Reply.

Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR.

Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. No abstract available.

16.

A Systematic Review on Ischemic Priapism and Immediate Implantation: Do We Need More Data?

Capece M, La Rocca R, Mirone V, Bivalacqua TJ, Castiglione F, Albersen M, Ralph DJ, Muneer A, Garaffa G.

Sex Med Rev. 2019 Jul;7(3):530-534. doi: 10.1016/j.sxmr.2018.10.007. Epub 2019 Mar 19. Review.

PMID:
30898595
17.

Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.

Gupta M, Kates M, Bivalacqua TJ.

Curr Opin Oncol. 2019 May;31(3):183-187. doi: 10.1097/CCO.0000000000000533.

PMID:
30893148
18.

Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer.

Brant A, Daniels M, Chappidi MR, Joice GA, Sopko NA, Matoso A, Bivalacqua TJ, Kates M.

World J Urol. 2019 Mar 8. doi: 10.1007/s00345-019-02673-2. [Epub ahead of print]

PMID:
30850856
19.

The Urogenital Epithelium and Corporal Tissues Are the Primary Targets of Rejection in Penile Vascularized Composite Allotransplantation: A New Real-Time Tissue-Based Monitoring System.

Lough DM, Sopko NA, Matsui H, Miller D, Swanson EW, Bluebond-Langner R, Brandacher G, Burnett AL, Bivalacqua TJ, Redett RJ.

Plast Reconstr Surg. 2019 Mar;143(3):534e-544e. doi: 10.1097/PRS.0000000000005377.

PMID:
30817651
20.

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.

Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR.

Stem Cells Transl Med. 2019 May;8(5):441-449. doi: 10.1002/sctm.18-0230. Epub 2019 Feb 8.

Supplemental Content

Loading ...
Support Center